VIRAPLACEL
Advanced Mesenchymal Stem Cell Therapy for Acute GvHD
GvHD: A Complex Challenge
Acute Graft-versus-Host Disease remains a significant complication following allogeneic stem cell transplantation, presenting a formidable obstacle in the path towards successful treatment outcomes. Characterized by an immune response from donor cells against the recipient’s tissues, aGvHD manifests in various organs, leading to severe morbidity and mortality rates.
ViraPlacel: Revive Living Years
VIRAPLACEL represents a cutting-edge therapeutic intervention using Placenta Mesenchymal Stem Cells (MSCs) for the treatment of acute Graft-versus-Host Disease (GvHD). This innovative product harnesses the power of MSCs to modulate immune responses and promote tissue repair, offering new hope for patients undergoing hematopoietic stem cell transplantation (HSCT).
Mechanism of Action
VIRAPLACEL’s MSCs exert their effects through several mechanisms:
- Immunomodulation: MSCs interact with various immune cells, downregulating the aggressive immune response characteristic of GvHD.
- Anti-inflammatory: They reduce inflammatory cytokines and increase regulatory T cells, contributing to a balanced immune environment.
- Tissue Repair: MSCs facilitate the repair of damaged tissues by secreting growth factors and supporting angiogenesis.
Mechanism of Action
VIRAPLACEL’s MSCs exert their effects through several mechanisms:
- Immunomodulation: MSCs interact with various immune cells, downregulating the aggressive immune response characteristic of GvHD.
- Anti-inflammatory: They reduce inflammatory cytokines and increase regulatory T cells, contributing to a balanced immune environment.
- Tissue Repair: MSCs facilitate the repair of damaged tissues by secreting growth factors and supporting angiogenesis.
Clinical Benefits
- Reduced Mortality: Patients receiving VIRAPLACEL have shown a significant reduction in mortality rates associated with acute GvHD.
- Improved Response Rates: Clinical trials indicate improved overall response rates to treatment, with most patients achieving complete remission.
- Enhanced Quality of Life: By mitigating the symptoms of GvHD, VIRAPLACEL improves the overall quality of life for patients’ post-transplantation.
Safety and Efficacy
VIRAPLACEL has undergone rigorous clinical testing to ensure its safety and efficacy. Real-world data suggest a high overall response rate (ORR) in children and adults with steroid-refractory aGvHD, receiving MSC therapy.
Administration
VIRAPLACEL is administered as an IV infusion under the guidance of a qualified healthcare professional. The dosage is 1×106 per Kg of patient and 2-4 times repeated doses every 48-72 hours which are determined based on the patient’s condition and response to therapy.
Our Commitment to Excellence
At ViraCellule, we are driven by a steadfast commitment to excellence, innovation, and patient-centered care. With VIRAPLACEL, we embark on a journey to redefine the standard of care for aGvHD, empowering oncologists with a powerful tool to combat this formidable adversary.
